Recent microarray data deposited in the R2 Neuroblastoma tumor database (http://r2.amc.nl) and (NCBI- Geo) show high expression of LGR5 in MYCN amplified tumors compared with non-amplified tumors (ANOVA p < 0.0001), high expression of LGR5 was also associated with disease recurrence/progression (ANOVA p = 0.0013) as well as stage 4 and 4s disease (ANOVA p = 0.02). This evidence concerns the gene MYCN and neuroblastoma.